ArticleMikrochimica acta2026
Multifunctional DNA nanoplatform based on near-infrared AgInS
Article in Mikrochimica acta, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
To enhance the therapeutic efficacy of breast cancer cells, a multifunctional nanoplatform was developed based on near-infrared AgInS2 quantum dots (AIS QDs) and rolling circle amplification (RCA). The AIS QDs were synthesized via an environmentally benign hydrothermal method using glutathione as a surface ligand, demonstrating favorable optical and photothermal properties. The RCA-generated long DNA strands served as a scaffold to co-assemble AS1411 aptamer-conjugated AIS QDs, gene therapeutic agent (DNAzyme), and doxorubicin (Dox), forming a multimodal nanoplatform (AIS QDs@RD). The polyvalent aptamer sequence carried by AIS QDs@RD enabled specific recognition of the overexpressed nucleolin on the membrane of MCF-7 cells (human breast cancer cells), allowing rapid discrimination between cancer and normal cells. AIS QDs@RD had excellent performance, including optimal excitation/emission wavelengths at 470/650 nm, a high photoluminescence quantum yield (PL QY) of 58.72%, a photothermal conversion efficiency (η) of 37.74%, and a Dox loading efficiency of 80.53%, which could significantly improve fluorescence imaging and drug delivery. Cytotoxicity assays revealed that treatment with AIS QDs@RD for 48 h, the viability of MCF-7 cells decreased to 31.8%, indicating potent antitumor activity, while minimal toxicity to normal cells. Therefore, this nanoplatform presents a promising strategy for targeted fluorescence imaging and therapy of breast cancer.
Indexed as
Identifiers
41865091What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.